KRAS and colorectal carcinoma: To test this hypothesis, we examined a panel of 21 KRASG12/G13 mutant CRC cell lines that were previously characterized for their intrinsic sensitivity to cetuximab31 to determine whether the degree of resistance to this drug correlated with the expression level of mutant KRAS protein.